[HTML][HTML] A review of biological targets and therapeutic approaches in the management of triple-negative breast cancer

H Kumar, NV Gupta, R Jain… - Journal of Advanced …, 2023 - Elsevier
Background Triple-negative breast cancer (TNBC) is a heterogeneous, aggressive
phenotype of breast cancer with associated chemoresistance. The development of chemo-or …

Hypoxia: syndicating triple negative breast cancer against various therapeutic regimens

N Srivastava, SS Usmani, R Subbarayan… - Frontiers in …, 2023 - frontiersin.org
Triple-negative breast cancer (TNBC) is one of the deadliest subtypes of breast cancer (BC)
for its high aggressiveness, heterogeneity, and hypoxic nature. Based on biological and …

Immunogenic cell death-relevant damage-associated molecular patterns and sensing receptors in triple-negative breast cancer molecular subtypes and implications …

M Xu, J Lu, Y Zhong, J Jiang, Y Shen, J Su… - Frontiers in oncology, 2022 - frontiersin.org
Objectives Triple-negative breast cancer (TNBC) is defined as a highly aggressive type of
breast cancer which lacks specific biomarkers and drug targets. Damage-associated …

Research progress on immunotherapy in triple‑negative breast cancer

X Zhang, X Ge, T Jiang, R Yang… - … Journal of Oncology, 2022 - spandidos-publications.com
Triple‑negative breast cancer (TNBC) is a highly heterogeneous and aggressive
malignancy. Due to the absence of estrogen receptors and progesterone receptors and the …

G6PD activation in TNBC cells induces macrophage recruitment and M2 polarization to promote tumor progression

Y Li, X Han, Z Lin, C Wang, Z Fu, Q Sun, C Li - Cellular and Molecular Life …, 2023 - Springer
Abstract Glucose-6-phosphate dehydrogenase (G6PD) is involved in triple-negative breast
cancer (TNBC) progression. Metabolic crosstalk between cancer cells and tumor-associated …

[HTML][HTML] Functions and therapeutic potentials of exosomes in osteosarcoma

J Yue, ZS Chen, XX Xu, S Li - Acta materia medica, 2022 - ncbi.nlm.nih.gov
Osteosarcoma is a primary malignant tumor of the skeleton with the morbidity of 2.5 in 1
million. The regularly on-set is in the epiphysis of the extremities with a high possibility of …

Extracellular vesicles: A new diagnostic biomarker and targeted drug in osteosarcoma

X Gao, B Gao, S Li - Frontiers in Immunology, 2022 - frontiersin.org
Osteosarcoma (OS) is a primary bone cancer that is highly prevalent among adolescents
and adults below the age of 20 years. The prognostic outcome of metastatic OS or relapse is …

Camptothecin loaded casein nanosystem for tuning the therapeutic efficacy against highly metastatic triple-negative breast cancer cells

S Khatun, M Pebam, CL Putta, AK Rengan - Biomaterials Science, 2023 - pubs.rsc.org
The heterogenic of TNBC and the side effects of chemo drugs lead to the failure of therapy.
Protein-based nanoplatforms have emerged as an important domain in protein-engineered …

[HTML][HTML] Towards dual function of autophagy in breast cancer: A potent regulator of tumor progression and therapy response

M Hashemi, MDA Paskeh, S Orouei, P Abbasi… - Biomedicine & …, 2023 - Elsevier
As a devastating disease, breast cancer has been responsible for decrease in life
expectancy of females and its morbidity and mortality are high. Breast cancer is the most …

Recent advances of multifunctional PLGA nanocarriers in the management of triple-negative breast cancer

YH Dinakar, N Rajana, NU Kumari, V Jain… - AAPS PharmSciTech, 2023 - Springer
Even though chemotherapy stands as a standard option in the therapy of TNBC, problems
associated with it such as anemia, bone marrow suppression, immune suppression, toxic …